{"prompt": "['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'assessments is being deferred and the study, with the exception of the optional', 'assessments, can be initiated.', '10.3.', 'Quality Control (Study Monitoring)', 'In accordance with applicable regulations including GCP, and GSK procedures,', 'GSK monitors will contact the site prior to the start of the study to review with the', 'site staff the protocol, study requirements, and their responsibilities to satisfy', 'regulatory, ethical, and GSK requirements.', 'When reviewing data collection procedures, the discussion will also include', 'identification, agreement and documentation of data items for which the eCRF', 'will serve as the source document.', 'GSK will monitor the study and site activity to verify that the:', 'Data are authentic, accurate, and complete.', 'Safety and rights of subjects are being protected.', 'Study is conducted in accordance with the currently approved protocol and any', 'other study agreements, GCP, and all applicable regulatory requirements.', 'The investigator and the head of the medical institution (where applicable) agrees to', 'allow the monitor direct access to all relevant documents', '10.4.', 'Quality Assurance', 'To ensure compliance with GCP and all applicable regulatory requirements, GSK', 'may conduct a quality assurance assessment and/or audit of the site records, and', 'the regulatory agencies may conduct a regulatory inspection at any time during or', 'after completion of the study.', 'In the event of an assessment, audit or inspection, the investigator (and institution)', 'must agree to grant the advisor(s), auditor(s) and inspector(s) direct access to all', 'relevant documents and to allocate their time and the time of their staff to discuss', 'the conduct of the study, any findings/relevant issues and to implement any', 'corrective and/or preventative actions to address any findings/issues identified.', '10.5.', 'Study and Site Closure', 'Upon completion or premature discontinuation of the study, the GSK monitor will', 'conduct site closure activities with the investigator or site staff, as appropriate, in', 'accordance with applicable regulations including GCP, and GSK Standard', 'Operating Procedures.', 'GSK reserves the right to temporarily suspend or prematurely discontinue this', 'study at any time for reasons including, but not limited to, safety or ethical issues', 'or severe non-compliance. For multicenter studies, this can occur at one or more', 'or at all sites.', 'If GSK determines such action is needed, GSK will discuss the reasons for taking', 'such action with the investigator or the head of the medical institution (where', '62']['2016N277425_0', 'CONFIDENTIAL', '2018N377698_00', '201749', 'applicable). When feasible, GSK will provide advance notification to the', 'investigator or the head of the medical institution, where applicable, of the', 'impending action.', 'If the study is suspended or prematurely discontinued for safety reasons, GSK will', 'promptly inform all investigators, heads of the medical institutions (where', 'applicable) and/or institution(s) conducting the study. GSK will also promptly', 'inform the relevant regulatory authorities of the suspension or premature', 'discontinuation of the study and the reason(s) for the action.', 'If required by applicable regulations, the investigator or the head of the medical', 'institution (where applicable) must inform the IRB/IEC promptly and provide the', 'reason for the suspension or premature discontinuation.', '10.6.', 'Records Retention', 'Following closure of the study, the investigator or the head of the medical', 'institution (where applicable) must maintain all site study records (except for', 'those required by local regulations to be maintained elsewhere), in a safe and', 'secure location.', 'The records must be maintained to allow easy and timely retrieval, when needed', '(e.g., for a GSK audit or regulatory inspection) and must be available for review', 'in conjunction with assessment of the facility, supporting systems, and relevant', 'site staff.', 'Where permitted by local laws/regulations or institutional policy, some or all of', 'these records can be maintained in a format other than hard copy (e.g., microfiche,', 'scanned, electronic); however, caution needs to be exercised before such action is', 'taken.', 'The investigator must ensure that all reproductions are legible and are a true and', 'accurate copy of the original and meet accessibility and retrieval standards,', 'including re-generating a hard copy, if required. Furthermore, the investigator', 'must ensure there is an acceptable back-up of these reproductions and that an', 'acceptable quality control process exists for making these reproductions.', 'GSK will inform the investigator of the time period for retaining these records to', 'comply with all applicable regulatory requirements. The minimum retention time', 'will meet the strictest standard applicable to that site for the study, as dictated by', 'any institutional requirements or local laws or regulations, GSK', 'standards/procedures, and/or institutional requirements.', 'The investigator must notify GSK of any changes in the archival arrangements,', 'including, but not limited to, archival at an off-site facility or transfer of', 'ownership of the records in the event the investigator is no longer associated with', 'the site.', '63']\n\n###\n\n", "completion": "END"}